Status:
COMPLETED
Ascorbyl Peroxide Association With Bronchopulmonary Dysplasia
Lead Sponsor:
St. Justine's Hospital
Collaborating Sponsors:
Canadian Institutes of Health Research (CIHR)
Conditions:
Bronchopulmonary Dysplasia
Eligibility:
All Genders
23-32 years
Brief Summary
Urinary ascorbyl peroxide level in the first week of life will be a good predictor of Bronchopulmonary dysplasia (BPD) in preterm infants less than 33 weeks of gestation.
Detailed Description
This study uses ascorbyl peroxide as representative of oxidative stress in premature infants on parenteral nutrition and aims to test the correlation of this metabolite and the different major neonata...
Eligibility Criteria
Inclusion
- Preterm infants less than 33 weeks of gestation\<
- Admission to CHU Sainte-JUstien neonatal intensive care unit
- Receiving Parenteral nutrition during the first week of life
- Parental consent
Exclusion
- Major congenital anomalies
- Sever perinatal asphyxia
Key Trial Info
Start Date :
August 1 2010
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 1 2015
Estimated Enrollment :
51 Patients enrolled
Trial Details
Trial ID
NCT01439295
Start Date
August 1 2010
End Date
November 1 2015
Last Update
November 18 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Montreal, Sainte-Justine Hospital
Montreal, Quebec, Canada, H3T1C5